Additional compensatory mechanisms altering antisense oligonucleotide suppression of BCL2: Effects upon AKT1 and STAT3

In Vivo

Volumn 28, Issue 5, 2014, Pages 867-870

  Rubenstein, Marvin ^a,b,c   Hollowell, Courtney M P ^b   Guinan, Patrick ^a,b,c,d  

^a Hektoen Institute for Medical Research   (United States)

^b Jr Hospital of Cook County   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense; BCL 2; Prostate cancer; Therapy

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; B CELL LYMPHOMA 2 PROTEIN; CASPASE 3; E1A ASSOCIATED P300 PROTEIN; INTERLEUKIN 6; LIPOFECTIN; NANOPARTICLE; OLIGONUCLEOTIDE; STAT3 PROTEIN; UNCLASSIFIED DRUG; PROTEIN BCL 2; PROTEIN KINASE B;

ANTISENSE THERAPY; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; GENE ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; ONCOGENE; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; TUMOR RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84918498764     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rubenstein M, Hollowell CMP and Guinan P: Inhibition of BCL-2 by antisense oligonucleotides is followed by a compensatory suppression of caspase-3 in LNCaP cells. Eur J Clin and Med Oncol 3: 1-6, 2011.
2. Mu Z, Hachem P and Pollack A: Antisense BCL-2 sensitizes prostate cancer cells to radiation. Prostate 65: 331-340, 2005.
3. Yip KW, Mocanu JD, Au PY, Sleep GT, Busson D, Yeh P, Gilbert WC, O'Sullivan R, Gullane B, Bastianutto C and Liu FF: Combination BCL-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11: 8131-8844, 2005.
4. Yamanaka K, Miyake H, Zangemeister-wittke U, Jansen B and Gleave M: Novel bispecific antisense oligonucleotides inhibiting both BCL-2 and BCL-xL expression induce apoptosis and enhance chemosensitivity in human androgen- independent prostate cancer cells. Proceedings AACR 45: Abstract #2930, 2004.
5. Rubenstein M, Hollowell CMP and Guinan P: In LNCaP cells enhanced expression of the androgen receptor compensates for BCL-2 suppression by antisense oligonucleotides. Ther Adv Urology 3: 73-79, 2011.
6. Rubenstein M, Hollowell CMP and Guinan P: In LNCaP cells enhanced expression of both androgen receptor and co-stimulatory protein p300 compensate for antisense oligonucleotide suppression of BCL-2. Ther Adv Urology 3: 243-250, 2011.
7. Rubenstein M, Hollowell CMP and Guinan P: Increased expression of the androgen receptor with p300 and IL6 coactivators compensate for oligonucleotide suppression of BCL- 2. No increased CREBBP or IL4 expression. Ther Adv Urology 5: 85-93, 2013.
8. Rubenstein M, Hollowell, CMP and Guinan P: Multiple pathways compensate for antisense suppression of BCL-2 in LNCaP cells contributing to tumor resistance. J Physiobiochem Metab 1: 2, 2012.
9. Rubenstein M, Hollowell CMP and Guinan P: Increased prostate specific membrane antigen expression in LNCaP Cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR. Med Oncol 27: 1212-1218, 2010.
10. Rubenstein M, Hollowell CMP and Guinan P: Bispecific oligonucleotides may induce interferon in LNCaP cells enhancing surface antigen expression: Effect of intra-strand base pair complementarity. In Vivo 25: 61-67, 2011.
11. Rubenstein M, Hollowell CMP and Guinan P: No compensation in CD44 stem cell marker following BCL-2 suppression by antisense oligonucleotides. In Vivo 27: 251-256, 2013.
12. Abdulghani J, Gu L, Dagvadori A, Lutz J, Leiby B, Bonuccelli, G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L and Nevalainen MT: STAT3 promotes metastatic progression of prostate cancer. Am J Pathol 172: 1717-1728, 2008.
13. Oncogenex website: www.Oncogenex.ca
14. Rubenstein M and Guinan P: Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells. In Vivo 24: 489-93, 2010.
15. Siegal R, Ma J, Zou Z and Jemal A: Cancer Statistics, 2014. Ca Cancer JClin 64: 9-29, 2014.